Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA268414
Max Phase: Preclinical
Molecular Formula: C11H14IN5
Molecular Weight: 343.17
Molecule Type: Small molecule
Associated Items:
ID: ALA268414
Max Phase: Preclinical
Molecular Formula: C11H14IN5
Molecular Weight: 343.17
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)N=C(N)N=C(N)N1c1cccc(I)c1
Standard InChI: InChI=1S/C11H14IN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-4-7(12)6-8/h3-6H,1-2H3,(H4,13,14,15,16)
Standard InChI Key: BBDVJFGPASAVDW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 343.17 | Molecular Weight (Monoisotopic): 343.0294 | AlogP: 1.48 | #Rotatable Bonds: 1 |
Polar Surface Area: 80.00 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 8.04 | CX LogP: 2.03 | CX LogD: 1.30 |
Aromatic Rings: 1 | Heavy Atoms: 17 | QED Weighted: 0.76 | Np Likeness Score: -0.80 |
1. Ghose AK, Crippen GM.. (1983) Combined distance geometry analysis of dihydrofolate reductase inhibition by quinazolines and triazines., 26 (7): [PMID:6864738] [10.1021/jm00361a012] |
2. Doweyko AM.. (1988) The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules., 31 (7): [PMID:3290487] [10.1021/jm00402a025] |
3. Coats EA, Genther CS, Dietrich SW, Guo ZR, Hansch C.. (1981) Comparison of the inhibition of methotrexate-sensitive and -resistant Lactobacillus casei cell cultures with purified Lactobacillus casei dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-substituted-phenyl)-s-triazines. Use of quantitative structure-activity relationships in making inferences about the mechanism of resistance and the structure of the enzyme is situ compared with the enzyme in vitro., 24 (12): [PMID:6796688] [10.1021/jm00144a010] |
4. Hansch C, Hathaway BA, Guo ZR, Selassie CD, Dietrich SW, Blaney JM, Langridge R, Volz KW, Kaufman BT.. (1984) Crystallography, quantitative structure-activity relationships, and molecular graphics in a comparative analysis of the inhibition of dihydrofolate reductase from chicken liver and Lactobacillus casei by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazine s., 27 (2): [PMID:6420569] [10.1021/jm00368a006] |
5. Khwaja TA, Pentecost S, Selassie CD, Guo Z, Hansch C.. (1982) Comparison of quantitative structure-activity relationships of the inhibition of leukemia cells in culture with the inhibition of dihydrofolate reductase from leukemia cells and other cell types., 25 (2): [PMID:7057420] [10.1021/jm00344a012] |
6. Selassie CD, Guo Z, Hansch C, Khwaja TA, Pentecost S.. (1982) A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate., 25 (2): [PMID:7057421] [10.1021/jm00344a013] |
7. Coats EA, Genther CS, Selassie CD, Strong CD, Hansch C.. (1985) Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate., 28 (12): [PMID:3934385] [10.1021/jm00150a026] |
8. Crippen GM.. (1997) Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data., 40 (20): [PMID:9379435] [10.1021/jm970211n] |
9. Selassie CD, Hansch C, Khwaja TA, Dias CB, Pentecost S.. (1984) Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate., 27 (3): [PMID:6699880] [10.1021/jm00369a019] |
10. Ghose AK, Crippen GM.. (1984) General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors., 27 (7): [PMID:6737433] [10.1021/jm00373a016] |
Source(1):